Introduction
High-dose chemotherapy followed by hematopoietic SCT (HSCT) is widely used in the treatment of patients with hematological and non-hematological malignancies. One of the most important causes of morbidity in HSCT is infection during the time of prolonged neutropenia. [1] [2] [3] [4] Recovery of neutrophilic granulocytes after HSCT depends on multiple factors such as the quality and quantity of progenitor cell products and the use of myeloid growth factors, such as G-CSF, among other patient-specific factors. G-CSF has been used both pre-transplantation as a part of stem cell priming regimens and post transplantation to enhance stem cell engraftment to minimize the morbidity and mortality associated with prolonged neutropenia. [5] [6] [7] [8] [9] The use of G-CSF after HSCT accelerates granulocyte engraftment and recovery by 1-6 days in comparison with control. [10] [11] [12] [13] However, most of the studies have been carried out on small numbers of patients and have varied significantly in patient demographics, G-CSF dosage regimen and other factors affecting outcomes. Overall, there is no consensus on the optimal use of G-CSF after high-dose chemotherapy followed by HSCT.
The most recent American Society of Clinical Oncology 2006 guidelines recommend the use of G-CSF after autologous, but not after allogeneic, HSCT. 14 The authors point out that among autologous transplant patients, there seem to be cost savings in decreasing the duration of hospitalization when using G-CSF post transplantation. 14 However, the same is not true of allogeneic transplant recipients. Although the duration of neutropenia is shortened, the length of hospitalization is not affected, and as a result, there does not seem to be cost savings when using G-CSF in allogeneic transplant patients. 14 The American Society of Clinical Oncology guidelines recommend that G-CSF should be initiated on day þ 1 for autologous transplant to day þ 5 and should be continued until the ANC is 2000-3000/ml. Despite these guidelines, the main controversy in the autologous transplant setting is regarding the necessity of using G-CSF in patients infused with over 5.0 Â 10 6 CD34 þ cells/kg and the optimal time to start G-CSF. In addition, many transplant centers, nationwide, are using G-CSF in allogeneic transplant patients for the benefit of earlier engraftment. This review was performed to evaluate the evidence presented by studies analyzing the use of G-CSF after autologous and allogeneic transplantation.
A systematic and comprehensive search of literature was performed using MEDLINE databases from 1990 to 2007 and a hand search of references. Studies were included if they were prospective-randomized, prospective non-randomized or retrospective. The reason for including retrospective studies was that most of the studies were conducted in a small number of patients and a very small percentage (o10%) of the prospective-randomized studies were blinded. In addition, the studies were restricted to full publication only because of limited data compared with the papers published in full. We also limited our search to using publications in the English language only. For autologous transplantation, the articles reviewed were restricted to investigating only PBSCT, whereas studies reporting either BMT or PBSCT were included in the review of allogeneic transplantation to evaluate whether some of the outcomes depended on the source of hematopoietic stem cell products. The level of evidence for each of the outcomes analyzed was graded on the basis of guidelines provided by the Oxford Centre for Evidence-based Medicine. 15 Only the randomized controlled studies (RCTs), with either observation or placebo as a control, were considered for the assignment of level of evidence. Homogeneity of a given finding was deemed significant if 90% or more RCTs with a combined number of at least 100 patients in each group showed consistent results. Anything less than a total of 100 patients in each group was considered of narrow confidence interval.
Review of literature: autologous transplantation
G-CSF vs control after PBSCT Study characteristics. Various studies have evaluated the efficacy of using G-CSF in comparison to either placebo 11, 16, 17 or observation. 10, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] These studies are summarized in Tables 1-3 . Most of the studies involved patients with hematological malignancies (leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma), with some also enrolling patients with nonhematological malignancies. 10, 17, [20] [21] [22] 24, 25, 27, 29, 30 Two studies specifically evaluated breast cancer patients undergoing autologous transplantation. 22, 25 Most of the studies used filgrastim as a form of G-CSF, whereas three studies used lenograstim at either 263 mg per day 26 or at 150 mg/m 2 per day. 17, 29 Filgrastim is derived from Escherichia coli, differing from lenograstim, which is non-glycosylated and has an extra methionine at the N-terminus. [31] [32] [33] [34] In vitro studies have suggested that lenograstim is more potent and stable than filgrastim. 35 However, filgrastim and lenograstim have been found to be equally effective at reducing the duration of neutropenia after high-dose chemotherapy and autologous PBSCT. 36 Most of the studies started G-CSF on day þ 1 post transplantation with the exception of a few studies starting on day þ 5. 21, 23, 24 In addition, some studies compared the control group with the early vs delayed or individualized time to start G-CSF, which is discussed in detail in the next sections. G-CSF was administered on the basis of the patients' body weight in most studies at 5 mg/kg per day as either i.v. infusion or SQ injection 10, 16, [18] [19] [20] 22, [24] [25] [26] 28, 30 or at 10 mg/kg per day i.v. or SQ. 21 Three studies used a BSAbased dosing for filgrastim (50 mg/m 2 per day) or lenograstim (150 mg/m 2 per day), 11, 17, 27 whereas Lee et al.
23
used a fixed dose of filgrastim (300 mg per day) in patients who weighed 70 kg or less and a weight-based dose (5 mg/kg per day) in patients heavier than 70 kg. The criteria for discontinuing G-CSF treatment after PBSCT differed significantly in various studies: when ANC 4500/ ml, 11, 20, 27 ANC 41000/ml, 21, 22 ANC 41500/ml, 16,24 ANC 45000/ml, 19 or WBC 410 000/ml; 25 or after ANC 4500/ml for 2 28 or 3 17, 26, 29, 30 consecutive days; or after ANC 41000/ ml for 2 consecutive days; 23 or after WBC 41000/ml for 3 consecutive days; 18 or was left to the treating physician. 10 Various PBSC mobilization protocols, conditioning regimens and prophylaxis therapies were used in these studies. In addition, the number of CD34 þ cells infused varied significantly in different studies; their median values are reported in Tables 1-3 . Owing to the small number of studies, we have overlooked the variability of the parameters mentioned above in various studies and assume that the outcomes analyzed below are not influenced by this variability.
Outcomes. Time to neutrophil engraftment was significantly shorter when G-CSF was used after transplantation compared with observation or placebo in most of the studies. 10, 11, 17, 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Only one retrospective and one prospective non-randomized study did not find a statistically significant difference in time to neutrophil engraftment between the group receiving G-CSF and the observation group. 19, 21 As all the RCTs with a combined number of more than 100 patients in each group showed the beneficial effects of G-CSF on neutrophil engraftment, 10, 11, 16, 17, [22] [23] [24] 26, 29 this was considered level 1A evidence. In most of the studies, ANC 4500/ml was achieved by day þ 9 to day þ 11 when G-CSF was used. The difference in days to neutrophil engraftment between the groups receiving or not receiving G-CSF ranged from 2 to 9.5 days, 10, 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] showing that the use of G-CSF was beneficial in terms of earlier neutrophil engraftment. In addition, several studies noted that even though the high number of CD34 þ cells infused correlated with earlier neutrophil engraftment, the benefit of using G-CSF was independent of the number of CD34 þ cells infused. 26, 29, 37 It is speculated that G-CSF administration may delay megakaryocyte expansion because of the preferential proliferation of common myeloid progenitors into neutrophils. 24, [38] [39] [40] [41] However, there was no significant difference in time to plts engraftment (plts 420 000/ml) between the group receiving G-CSF and the control group in most studies. 10, 11, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Only one randomized, single-blind, placebo-controlled study showed a significant increase in plts engraftment when G-CSF was used (starting on day þ 5) compared with placebo. 16 As eight out of nine RCTs (o90%) with well over 100 patients in each group showed no significant difference in plts engraftment with the use of G-CSF, 10, 11, 17, [22] [23] [24] 26, 29 this was considered level 1B evidence. In most of the studies, plts engraftment was achieved by day þ 10 to day þ 15. 10, 11, 17, [19] [20] [21] [22] [23] [24] [25] 27, 28 In one study, 29 plts engraftment was significantly earlier (on day þ 5 to day þ 7) compared with the normal trend; however, no possible explanation was provided by the authors. It is known that the number of reinfused CD34 þ cells predicts plts recovery. 42, 43 Even though 45.0 Â 10 6 CD34 þ cells/kg were administered on average in this study, it does not explain why plts engraftment was considerably earlier as several other studies with 45.0 Â 10 6 /kg CD34 þ cells reinfused did not observe earlier plts engraftment. 20, 26, 28 Several studies defined plts engraftment as plts 415 000/ ml, 18, 21 425 000/ml 30 or 450 000/ml 24, 26, 27 without showing a significant difference in time to plts engraftment between groups receiving and not receiving G-CSF. Units of RBC /kg.
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and plt infusion were also not significantly different when comparing G-CSF vs control. 10, 11, [16] [17] [18] [19] [20] 22, 23, 25, 26, [28] [29] [30] There was no significant difference in days of febrile neutropenia when comparing the group receiving G-CSF with the control group in most studies. 10, 11, 19, [21] [22] [23] [24] [25] [26] [27] 29, 30 However, two non-randomized studies showed that the duration of fever or febrile neutropenia was significantly higher in the group that did not receive G-CSF. 20, 28 All the RCTs with a total of more than 100 patients in each group showed no effect of G-CSF on the days of febrile neutropenia 10, 11, 16, 17, [22] [23] [24] 26, 29 (level 1A). The febrile neutropenic period ranged from 1 to 6 days, which could have been influenced by the time to neutrophil engraftment and prophylactic therapies used. Days of non-prophylactic i.v. antibiotic use were not significantly different between groups that received or did not receive G-CSF in most studies. 11, 19, [21] [22] [23] [24] [25] [26] [27] 30 However, four independent studies (out of which two were RCTs) showed that the group that did not receive G-CSF required significantly more days of i.v. antibiotic treatment compared with the group receiving G-CSF. 10, 17, 20, 28 Out of all the RCTs, six studies with a total of more than 100 patients in each group showed no significant difference in the days of i.v. antibiotics, 11, 16, [22] [23] [24] 26 whereas two studies with a combined number of more than 100 patients in each group showed fewer days of i.v. antibiotics with G-CSF use. 10, 17 Hence, there is no consensus on the benefit of G-CSF in reducing the i.v. antibiotic use. There was a great variability in days of non-prophylactic antibiotic therapy in different studies, probably because of the various protocols used for initiating and discontinuing antibiotics in different institutions.
About a half of the studies showed that the posttransplant length of hospital stay was significantly different between groups with G-CSF and controls, 10, [16] [17] [18] 20, 22, 23, 28, 29 whereas the other half showed no significant difference. 11, 19, 21, 22, [24] [25] [26] 30 However, when only the RCTs were evaluated for reduction of post-transplant length of hospital stay, six studies with a total of well over 100 patients in each group showed a benefit of G-CSF, 10, 16, 17, 22, 23, 29 whereas three studies with less than a total of 100 patients in each group showed no effect of G-CSF. 11, 24, 26 Therefore, the use of G-CSF was considered to be beneficial in reducing the post-transplant length of hospital stay in patients undergoing autologous transplantation (level 1B). The variability in post-transplant hospital stay (range: 12-30 days) between studies may have been because of differences in discharge requirements.
Early (day 0 to day þ 4) vs delayed (Xday þ 5) initiation of G-CSF Study characteristics. The rationale for delaying the initiation of G-CSF is that late-committed neutrophilic progenitors responsive to G-CSF are not yet formed immediately after PBSCT, 44, 45 making the early G-CSF treatment futile. With this in mind, several studies have analyzed the optimal time to start G-CSF after autologous PBSCT. 20, 22, 25, 26, 29, 30, 37, [46] [47] [48] [49] The summary of these studies is provided in Table 2 . Most of the studies enrolled patients with hematological malignancies, with some also including patients with solid tumors. 20, 29, 30, 37, 48, 49 Two studies Significant difference from other groups.
Use of G-CSF after HSCT M Trivedi et al specifically evaluated breast cancer patients undergoing autologous transplantation. 22, 25 Most of the studies used filgrastim as a form of G-CSF, whereas two studies used lenograstim at either 263 mg per day 26 or at 150 mg/m 2 per day. 29 Filgrastim was administered on the basis of weight in most studies at 5 mg/kg per day as either i.v. infusion or SQ injection, 20, 22, 25, 30, 46, 48, 49 whereas a fixed dose of G-CSF (filgrastim 300 or 480 mg per day) was used in some studies. 37, 47 The criteria for discontinuing G-CSF treatment after PBSCT varied significantly in various studies: on the day of ANC 4500/ml, 20,47 ANC 41000/ml, 22 or WBC 410 000/ml; 25 or after ANC 4500/ml for 2 37, 48 or 3 consecutive days; 26, 29, 30, 49 or after ANC 41500/ml for 3 consecutive days. 46 In all the studies, patients received on average 42.0 Â 10 6 /kg CD34 þ cells.
Outcomes. In comparing the time to neutrophil engraftment (ANC 4500/ml), most of the studies did not find statistically significant differences between early (day 0 to day þ 4) and delayed (Xday þ 5) G-CSF administration. 20, 25, 26, 29, 30, 37, 47, 48 In one of the studies, the number of CD34 þ cells infused was significantly less in the delayed administration group compared with the early G-CSF treatment group. 37 However, this difference did not significantly affect the time to neutrophil engraftment. In other studies, the number of CD34 þ cells infused was equivalent in both the groups. On the other hand, three studies (out of which two were RCTs) found that the time to reach ANC 4500/ml was significantly longer in patients receiving a delayed G-CSF treatment. 22, 46, 49 In these studies, when G-CSF was started late (on or after day þ 5), the time to neutrophil engraftment was delayed by 1 22,46 or 1.5 days. 49 In addition, in the study conducted by deAzevedo et al., 46 the benefit of early G-CSF (day þ 1) compared with late G-CSF (day þ 5) in reaching ANC 4500/ml was only evident in a subgroup of patients who received melphalan as a conditioning regimen and received 43.0 Â 10 6 per kg CD34 þ cells. When only the RCTs were evaluated, five studies with a combined number of over 100 patients showed no difference in ANC recovery with delayed initiation of G-CSF, 26, 29, 37, 47, 48 whereas two studies with a total of o100 patients in each group reported delayed neutrophil engraftment with starting G-CSF later than day þ 5. 22, 46 Therefore, delayed G-CSF initiation was considered to be equally effective for early initiation in terms of neutrophil engraftment (level 1B). In most of the studies, neutrophil engraftment was achieved by day þ 9 to day þ 11. It is possible that the number of CD34 þ cells reinfused is responsible for this small variability, as suggested by earlier studies. 42, 43 However, other patientspecific factors and differences in conditioning regimens used by various studies may also have affected the days to neutrophil engraftment.
There was no significant difference in time to plt engraftment (plts 420 000/ml) between the early and delayed G-CSF administration groups in all the studies reviewed. 20, 22, 25, 26, 29, 30, 37, 47, 48 As all the RCTs with a total of more than 100 patients in each group reported the same finding, 22, 26, 29, 37, 47, 48 this was considered level 1A evidence. In most of the studies, plts 420 000/ml was achieved by day þ 10 to day þ 14. 20, 22, 25, 37, 47, 48 Units of RBC and plt infusion were also not significantly different when compared between the early and delayed G-CSF groups. 20, 22, 26, 29, 30, 37, 47 There was no significant difference in days of febrile neutropenia when comparing the early vs delayed G-CSF administration groups in all the studies reviewed. 20, 22, 25, 26, 29, 30, 37, 46, 47 All the RCTs with a total of more than 100 patients in each group reported the same finding 22, 26, 29, 37, 46, 47 (level 1A). The febrile neutropenic period ranged from 2 to 6 days. Days of non-prophylactic i.v. antibiotic use were similar in the early vs delayed G-CSF administration groups in most of the studies. 20, 22, 25, 26, 30, 37, 46, 47, 49 In one RCT, however, significantly longer treatment with antibiotics (10.5 vs 7 days) was required in patients who received G-CSF late compared with those with early G-CSF administration despite similar duration of febrile neutropenia. 46 This was thought to be due to more patients with bacteremia episodes in the delayed G-CSF administration group, requiring a fixed course of antibiotic treatment (10-14 days). In evaluating RCTs only, we found that five out of six studies with a combined number of over 100 patients in each group showed no significant difference in the days of nonprophylactic i.v. antibiotics with delayed compared with early initiation of G-CSF; 22, 26, 37, 46, 47 this was considered level 1B evidence. There was a great variability in days of non-prophylactic antibiotic therapy, probably because of the various protocols used for starting and stopping antibiotics in different institutes.
Post-transplant hospital stay was not significantly different between the early and delayed G-CSF administration groups in most of the studies. 20, 22, 25, 26, 29, 30, 37, 47 On the other hand, one RCT and one retrospective study showed a significantly longer post-transplant hospital stay with delayed administration of G-CSF compared with early initiation. 46, 49 As five out of six RCTs with a total of more than 100 patients in each group reported no significant difference between post-transplant hospital stay, 22, 26, 29, 37, 47 this was considered level 1B evidence. The variability in post-transplant hospital stay (range: 10-29 days) between studies is likely because of differences in discharge requirements. As expected, significantly longer treatment with G-CSF was required when G-CSF administration was started early after PBSCT rather than later. 26, 29, 30, 37, 46, 47, 49 Individualized initiation of G-CSF To our knowledge, there are only two studies published in peer-reviewed journals evaluating individualized initiation of G-CSF after autologous PBSCT; these are summarized in Table 3 . The study by Cetkovsky et al. 50 used 10 mg/kg per day G-CSF in patients with hematological malignancies until ANC was 41000/ml for 3 consecutive days. In one group of patients, G-CSF was initiated on day þ 1, whereas in the second group, it was started when ANC reached o500/ml (median start day: day þ 4). This particular patient-specific criterion was based on the rationale that, with conditioning regimens that slowly induce neutropenia, early G-CSF initiation might cause leukocytosis. The median numbers of CD34 þ cells infused
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was not significantly different in both groups of patients. There was no significant difference in time to neutrophil or platelet engraftment, duration of non-prophylactic antibiotic treatment, units of RBC and plt infusion, and post-transplant hospital stay between the two groups. A significantly shorter duration of treatment with G-CSF was required when patient-specific parameters were used to dictate the initiation of G-CSF compared with the fixed regimen starting on day þ 1. Another study 16 that assessed individualized criteria for initiation of G-CSF used 5 mg/kg per day filgrastim administered until ANC was 41500/ml after autologous PBSCT in patients with lymphoma (Table 3) . Patients were given G-CSF either on day þ 5 or on the basis of patientdependent factors (day þ 10 or when WBC X500/ml and ANC X100/ml, whichever is earlier). At least 5.0 Â 10 6 CD34 þ cells/kg were infused into patients. Time to neutrophil or plt engraftment, duration of febrile neutropenia and administration of non-prophylactic antibiotics, units of RBC and plt infusion, and post-transplant hospital stay between the two groups were not significantly different. A significantly shorter duration of treatment with G-CSF was required when initiation of G-CSF administration was individualized compared with a fixed regimen starting on day þ 5.
Filgrastim vs pegylated filgrastim
Four non-randomized studies have evaluated the safety and efficacy of using pegfilgrastim compared with filgrastim after high-dose chemotherapy and autologous PBSCT. [51] [52] [53] [54] In each of the four studies, the time to neutrophil and plt engraftment, as well as the post-transplant length of stay, was not significantly different between the patients who received pegfilgrastim compared with those who received filgrastim (Table 4) . Three of the studies compared the duration of febrile neutropenia. 51, 53, 54 In two of the three studies evaluating the duration of febrile neutropenia, there was no significant difference between pegfilgrastim compared with filgrastim. 51, 54 One study, however, showed a significantly shorter duration of febrile neutropenia with pegfilgrastim (1.6 days) compared with filgrastim (3 days). The authors attributed this difference to the small advantage pegfilgrastim showed in time to neutrophil engraftment (8.3 vs 9.5 days). In addition, there was no significant difference between the pegfilgrastim and filgrastim groups in the duration of non-prophylactic i.v. antibiotic treatment 53, 54 and the post-transplant hospital stay. 51, 53, 54 These studies show that the use of pegfilgrastim is equally efficacious to filgrastim in patients undergoing autologous PBSCT when various outcomes are considered. However, to make it a standard of practice, more RCTs need to be performed for evaluating the efficacy of pegfilgrastim over filgrastim in patients undergoing autologous PBSCT. Furthermore, the pharmacoeconomics of using the two agents need to be performed to determine whether a single dose of pegfilgrastim offers any cost benefit over daily injection of filgrastim in patients who are admitted to the hospital. The flexibility of discontinuation of filgrastim when the ANC goal is achieved will also need to be considered in these studies. Significant difference from other groups.
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Summary
Collectively, these results suggest that the use of G-CSF after autologous transplantation expedites neutrophil engraftment (level 1A) and shortens the length of hospital stay post transplantation (level 1B) without significantly affecting plt engraftment (level 1B) and days of febrile neutropenia (level 1A). In addition, the benefits of G-CSF are seen regardless of the number of CD34 þ cells infused, which justifies the recommendation for its use in all patients receiving autologous transplantation. In addition, many randomized or comparative studies have shown that the application of G-CSF can be safely postponed until day þ 5 or more after stem cell re-infusion. The delayed initiation (day þ 5 to day þ 7) of G-CSF does not significantly affect neutrophil engraftment (level 1B), platelet engraftment (level 1A), days of febrile neutropenia (level 1A), days of i.v. antibiotics (level 1B) or length of post-transplant hospital stay (level 1B). In the fixed initiation time schedule for G-CSF, two studies have shown that starting G-CSF as late as day þ 7 is equally beneficial (level 1B). 26, 47 In addition, the individualized regimen for starting G-CSF, as explained by Faber et al., 16 can also be used effectively, with the initiation of G-CSF being delayed beyond day þ 7. From the efficacy standpoint, the use of pegfilgrastim is acceptable on the basis of four non-randomized studies; however, the safety and costbenefit of using pegfilgrastim need to be justified and its efficacy has to be confirmed in the RCTs before it is considered a standard of practice.
Review of literature: allogeneic transplantation
G-CSF vs control after HSCT Study characteristics. Several studies have analyzed the efficacy of using G-CSF compared with control to decrease the number of neutropenic days after allogeneic transplantation in patients receiving either peripheral blood or BM cells. 12, 13, [55] [56] [57] [58] [59] [60] [61] [62] The outcomes from these studies are summarized in Table 5 . Most of these studies included patients with hematological malignancies, whereas some also enrolled patients with solid tumors. 57, 58 The majority of the studies administered filgrastim as an i.v. infusion or SQ injection, with the dose ranging from 5 to 10 mg/kg per day. 12, 13, 55, 57, 58, 62 Some studies did not report the route or dose used in their studies. 56, 60 The criteria for discontinuing G-CSF treatment after allogeneic transplant was variable in these studies: on the day of ANC 4500/ml; 58 or after ANC 4500/ml Â 2 days; 62, 63 or after ANC 4500/ml Â 3 days 13, 60 or ANC 41000/ml Â 3 days 12, 57, 64, 65 or ANC 43000/ml Â 1 day. 55 Owing to the small number of studies, we overlooked the variability of the parameters mentioned above in various studies and assume that the outcomes analyzed below are not influenced by this variability.
Outcomes. In all of the PBSCT studies, neutrophil engraftment was achieved by day þ 11 to day þ 16 ( Table 5 ). The use of G-CSF led to an improvement in neutrophil engraftment in most of the studies by 1-4 days compared with the placebo or observation arm (no G-CSF). 12, 13, 56, 57, 60, 61 As all the RCTs with a total of o100 patients in each group showed faster neutrophil engraftment with the use of G-CSF, 12, 57, 61 this was considered level 1B evidence. Similar results were also reported in BMT patients in retrospective studies. 56, 58, 60, 62 However, one retrospective study found a delayed engraftment by 2 days with the use of G-CSF vs observation in BMT patients. 55 The authors did not speculate on the reason for their contradictory result.
In three RCTs in patients undergoing PBSCT, the time to plt engraftment was not significantly different in patients who received G-CSF vs those who did not; 12, 57, 61 this was considered level 1B evidence because of a combined number of o100 in each group. Three non-randomized studies evaluating outcomes in BMT patients showed similar findings. 55, 58, 62 However, one retrospective study found a slight but statistically significant delay in plt engraftment when G-CSF was used in both PBSCT and BMT patients. 60 This delay in plt engraftment in the study by Ringden et al. 60 was presumed to be a result of G-CSF increasing plt aggregation and creating an accelerated intravascular consumption of plts. Conversely, one nonrandomized study showed that the use of G-CSF resulted in a significant decrease in the time to plt recovery in patients undergoing PBSCT. 13 This faster plt recovery was thought to be a result of less days of febrile neutropenia.
The majority of the PBSCT studies reported no significant difference in days of febrile neutropenia between patients who received vs those who did not receive G-CSF. 13, 55, 57 Similar results were also seen in BMT patients. 51 One study in PBSCT patients noted a significantly higher number of patients with febrile neutropenic episodes in the group without G-CSF (100%) than in the group treated with G-CSF (75%). 13 The number of infections, non-prophylactic i.v. antibiotic use, and the number of RBC and plt infusions were not significantly different when comparing G-CSF vs control. 12, 13, 55, 57, 58, 61 The median post-transplant length of hospital stay for these studies ranged from 16 to 24 days in PBSCT patients and from 22 to 56 days in patients undergoing BMT. There was no significant difference in post-transplant hospital stay with the administration of G-CSF in most studies evaluating allogeneic PBSCT. 12, 13, 56, 57, 61 As two RCTs with a total of o100 patients in each group reported no significant effect of G-CSF on post-transplant hospital stay, 57, 61 this was considered level 1B evidence. Only one study reported a non-significant trend toward shorter posttransplant hospital days (16 vs 20) with the use of G-CSF. 57 Similarly, in the patients undergoing BMT, post-transplant hospital stay was not influenced by the treatment with G-CSF. 55, 56, 62 Major concerns with the use of G-CSF in allogeneic patients are the reports of an increased incidence of GVHD with its use. The majority of studies evaluating PBSCT, including all three RCTs (with a total of o100 patients in each group), found no significant difference in incidence of acute or chronic GVHD with the use of G-CSF, 12, 13, 56, 57, 60, 61 making this a level 1B evidence. Three studies in BMT patients showed similar findings. 55, 56, 58 On the other hand, a significant increase in acute GVHD in patients undergoing BMT was reported by two retrospective studies. 60, 62 One retrospective study in BMT Use of G-CSF after HSCT M Trivedi et al Table 5 Summary of studies evaluating use of G-CSF in comparison to control in allogeneic HSCT 60 found a significant increase in acute GVHD (50 vs 39%) with the use of G-CSF when patients received BM products, whereas there was no significant difference in acute GVHD (33 vs 35%) with the use of G-CSF in patients undergoing PBSCT. In addition, this study was conducted at multiple institutions with comparison of outcomes between the centers using G-CSF and those not using it. When a multivariate analysis was carried out to account for center effect, the difference in the incidence of acute GVHD in patients receiving BMT was NS. It was proposed by the authors that as the donor cells were not exposed to G-CSF before infusion, they had a higher level of soluble IL-2 that might aggravate GVHD. 60, 66 The pre-treatment of donor T cells with G-CSF has been shown to increase the production of anti-inflammatory cytokines by T cells, which may reduce GVHD. 60, 67 Another study by Remberger et al. 62 also showed an increased incidence of acute GVHD (34 vs 9%) with the use of G-CSF. An increased incidence of acute GVHD was seen in individual groups of transplant patients (BMT and PBSCT). In this study, the incidence of GVHD in the G-CSF-treated group was mostly grade II or less (92%). There was no significant difference in TRM or deaths related to GVHD between the two groups. In addition, there was no significant difference in chronic GVHD between patients who received G-CSF vs those who did not. 62 A meta-analysis by Ho et al. 59 did not find an increase in the incidence of GVHD with the use of G-CSF. This meta-analysis had a total of 1198 patients with the majority (88%) undergoing BMT. On the basis of these studies, we can conclude that it is not clear at this point whether post-transplant G-CSF has any effect on GVHD incidence.
There was no statistically significant difference in TRM, disease free survival or OS between G-CSF and control in most of the PBSCT studies, including all three RCTs, 12, 13, 56, 57, 60, 61 which was considered level 1B evidence. Similar results were observed in BMT patients in most of the studies. 55, 56, 58, 62 However, one study showed a significantly detrimental TRM (27 vs 17%) and OS (48 vs 58%) with the use of G-CSF in BMT recipients in comparison to observation after 2 years. 60 The PBSCT patients treated with G-CSF in this study did not have a difference in TRM or OS compared with the patients who did not receive G-CSF. 60 The results in BMT patients can most likely be attributed to the fact that treatment with G-CSF was associated with more GVHD-related deaths (Table 6 ).
Early (day 0 to day þ 4) vs delayed (Xday þ 5) initiation of G-CSF Study characteristics. Most of the studies addressing the optimal time to initiate G-CSF were conducted in patients receiving BM products; [63] [64] [65] 68 however, one study also included patients receiving allogeneic PBSCT 68 (Table 6 ). Filgrastim was the most commonly used growth factor, whereas two studies used lenograstim at a dose of 263 mg per day. 64 The criteria for discontinuing G-CSF treatment after transplant was variable: on the day of Use of G-CSF after HSCT M Trivedi et al ANC 4500/ml Â 2 days, 63 ANC 41000/ml, 68 or WBC 41000/ml Â 3 days. 64, 65 Outcomes. The studies, including three RCTs in the BMT setting, did not find a significant difference in the time to neutrophil engraftment when giving G-CSF early (day 0 to þ 4) vs late (Xday þ 5) after allogeneic transplantation. [63] [64] [65] 68 In most of the studies, neutrophil engraftment was achieved by day þ 16 to day þ 18. There was also no difference in the time to plt engraftment, incidence of acute GVHD or post-transplant hospital stay between the early and delayed initiation of G-CSF. [59] [60] [61] 64 As all the three RCTs showed consistent results when comparing the early vs delayed initiation of G-CSF, the evidence was considered to be level 1B because of a combined number of o100 patients in each group.
In a study by Lee et al. 68 evaluating BMT patients, a significantly higher incidence of hepatic veno-occlusive disease was seen when G-CSF was given on day 0 vs day þ 5 (66.7 vs 40%). The authors proposed that giving G-CSF early after allogeneic transplant increased the amount of pro-inflammatory cytokines such as TNF-a, IL-6 and IL-8 released from macrophages and reticuloendothelial cells. This increase in cytokines may have contributed to the hepatic endothelial damage seen in veno-occlusive disease. The authors pointed out that differences in the pharmacokinetics of BU used as a part of the conditioning regimen could also have contributed to the difference in veno-occlusive disease incidence between the two groups. At a 100-day follow-up, a higher mortality rate was also seen in the group receiving G-CSF on day 0 (17%) than in the group that received G-CSF on day þ 5 (0%).
Summary
The decision to use G-CSF after an allogeneic HSCT has been met with some caution because of the reported risks of GVHD and lack of positive outcomes associated with its use. As reviewed in this report, the use of G-CSF given after allogeneic transplantation has been shown to be reasonably safe and effective in reducing the time to neutrophil engraftment by 1-2 days in most studies (level 1B for PBSCT). Multiple studies have shown a benefit of earlier engraftment with its use, which typically leads to fewer complications. Unfortunately, the benefit of early engraftment with G-CSF has not been shown to significantly decrease the length of hospital stay or improve the survival outcomes (level 1B for PBSCT). As shown by most of the studies, the use of G-CSF did not adversely affect the time to plt engraftment, and the risk of GVHD, at least in the PBSCT recipients (level 1B). Therefore, the use of G-CSF was considered safe in patients undergoing allogeneic transplantation as long as they receive PBSCT, rather than BMT. No substantial conclusion can be made about the safety and efficacy of G-CSF in the BMT setting, as there are no RCTs performed to evaluate the effects of G-CSF compared with either observation or placebo. Similar to the autologous transplantation, delayed initiation of G-CSF may be feasible in BMT patients (level 1B); however, this needs to be investigated in an RCT for patients undergoing PBSCT. It is possible that the risk of GVHD and effects on overall survival may depend on the time of initiation of G-CSF treatment post-allogeneic transplantation. This may be an important topic for future studies.
Expert commentary and recommendations
There are definite benefits and possible risks associated with the use of G-CSF in transplant patients. The main benefit to using G-CSF in transplant patients is the known reduction in time to achieve an adequate ANC. [10] [11] [12] [13] Whether faster engraftment results in decreased TRM, the less frequent use of antibiotics, shorter hospitalizations and overall reduction of costs are variable in autologous vs allogeneic transplant patients.
As we have discussed earlier, it is clear that the use of G-CSF in autologous transplant patients decreases the hospital stay and overall costs in several studies. 10, 16, 18, 20, 22, 23, 28, 29, 46, 49 There is no evidence to support using the number of CD34 þ cells infused per kg to decide whether patients should be treated with G-CSF. Therefore, we recommend the use of G-CSF in all autologous PBSC transplant patients regardless of the number of CD34 þ cells infused per kg. As several independent studies have shown that delaying the initiation of G-CSF treatment to day þ 5 or later results in comparable engraftment to earlier starting times, 16, 26, 47 we consider it reasonable to delay the initiation of G-CSF to day þ 5 to day þ 7. There is still some controversy about the use of G-CSF after allogeneic HSCT. Some studies have found that the use of G-CSF in allogeneic transplant patients has led to an increased incidence of severe GVHD and possibly decreased survival. 14, 60, 62 However, the risk of GVHD and decrease in survival has not been seen in patients receiving PBSCT. 12, 13, 56, 57, 60, 61 Therefore, G-CSF use is acceptable in the allogeneic PBSCT to achieve faster neutrophil engraftment, bearing in mind that this benefit does not likely translate into fewer infectious complications and early hospital discharge. However, as most of the retrospective studies in allogeneic BMT have shown a potential risk of GVHD with G-CSF, its use is not recommended without more controlled studies showing a favorable benefit-to-risk ratio in this setting.
